Navigation Links
The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Date:8/14/2013

BURLINGTON, Mass., Aug. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin, although currently not FDA-approved for treatment of ovarian cancer, is prescribed by approximately 70 percent of surveyed oncologists in first-line advanced ovarian cancer. Avastin is most frequently prescribed in first-line advanced ovarian cancer as an add-on agent to doublet platinum-based chemotherapy followed by continued administration of Avastin as a maintenance monotherapy. Approximately half of the surveyed oncologists who prescribe Avastin in first-line advanced ovarian cancer indicate that they encounter reimbursement barriers (such as prior authorization) when prescribing Avastin in this setting.

The U.S. Physician and Payer Forum report entitled Ovarian and Endometrial Cancer: How Will U.S. Prescriber and Payer Attitudes Toward Emerging Antiangiogenics and Other Targeted Anticancer Agents Shape the Treatment Landscape? finds that current treatment of ovarian and endometrial cancers relies heavily on generically available chemotherapies and that carboplatin/paclitaxel is very frequently prescribed in early-stage ovarian cancer, first-line advanced ovarian cancer and in early-stage and advanced endometrial cancer. However, the use of Avastin for treatment of ovarian cancer in all disease settings is common amongst surveyed oncologists and more than 65 percent of surveyed oncologists think that treatment rates with Avastin will increase in the next five years - primarily because they believe Avastin will gain regulatory approval for ovarian cancer. Avastin is rarely used by surveyed oncologists for treatment of endometrial cancer; however, surveyed oncologists believe that angiogenesis inhibitors can play a ro
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BD Completes Sale of Majority of Discovery Labware Unit
2. Allscripts adopts majority voting policy for directors
3. New National Survey Shows Majority of Americans Confident About Choosing Health Coverage
4. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
5. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
6. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
7. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
8. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
11. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... LONDON , July 14, 2014  VirtualScopics, ... (AIM: IXI) jointly announced today the formation of a ... Edward Ashton , Ph.D., chief scientific officer, VirtualScopics, ... members. "The formation of this joint Scientific ... commercial and operational alliance we signed with IXICO plc ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... Calif., April 29, 2011 First Quarter ... by 321 institutions, up from 239 in Q4 2010 ... revenue Operational focus enables lower planned expense growth in ... by Astellas NGX-1998 Phase 2 clinical trial continues in ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that the company will ... Securities Research Conference San Francisco, CA, May 9-11, 2011 ... Dr. J. Joseph Kim, Ph.D., President & CEO May ...
Cached Medicine Technology:NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/14/2014)... 14, 2014 Many people are unhappy ... plastic surgery to reduce a “double chin.” A ... the need to go under the knife. Jawflex is ... jaw muscles, therefore tightening the skin in that area ... Jawflex is used for facial exercise, double chin elimination ...
(Date:7/14/2014)... Many diet plans often recommend eating plenty ... School of Public Health at the University of Alabama ... effect on weight loss. Now experts are suggesting that the ... of portion control to trigger measurable weight loss. ... controlling how much is consumed, simply by using a specially-designed ...
(Date:7/14/2014)... Seattle, WA (PRWEB) July 14, 2014 ... start up company Passionate Playground announces its first product ... adult pleasure product storage system. , Inventor ... for passionate consumers to have a storage solution for ... in the multibillion dollar adult retail industry. , Semer ...
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
Breaking Medicine News(10 mins):Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... of its,mission to help consumers feel better and lead ... WNI ), introduces two new,products that help maintain health ... Nutrition is key to staying healthy, but sometimes the ... compounds into our bodies. Schiff(R),3-Day Cleanse is a simple ...
... To World-Class ... Knowledge-Based Economy, ... Business at,Carnegie Mellon University and its Donald H. Jones ... Pittsburgh: Building Bridges to a City,s New Future." The,symposium, ...
... Comprehensive Eating,Disorders Program at Lucile Packard Children,s Hospital ... 18 to 21. This allows the program to,now ... "I am delighted that the Eating Disorders ... group," said Naomi Brown, PhD, an eating,disorders treatment ...
... trials reported using independent safety monitoring committees that can ... reactions, according to a major review published in the ... University of Nottingham carried out a detailed analysis of ... to see what safety measures were in place to ...
... http://www.pharmacyfraudsettlement.com with filed documents, fraud, allegations, ... ... As front line professionals dispensing medications to,Medicaid beneficiaries pharmacists are particularly ... and report Medicaid fraud, which is noted in the site., ...
... Peake: VA Reaches Out to Vets, Families in ... veterans and,their families during major emergencies, especially natural ... to deploy mobile pharmacies,that will provide vital medicine ... will also open up the facilities to help ...
Cached Medicine News:Health News:Schiff(R) Introduces New Supplement Products for Intestinal Health and Beauty Maintenance 2Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 2Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 3Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 4Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 5Health News:Carnegie Mellon's Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25 6Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 2Health News:Eating Disorders Program at Lucile Packard Children's Hospital Expands to Include Young Adults 3Health News:Only 2 percent of child drug trials have independent safety checks 2Health News:Only 2 percent of child drug trials have independent safety checks 3Health News:CVS, America's Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges 2Health News:CVS, America's Largest Pharmacy Chain, Pays Nearly $37 Million to Settle Federal and State Generic Drug Switching Charges 3Health News:VA Putting Mobile Pharmacies on the Road 2
... Protection Device features the ability to use ... lesion and a pre-loaded nitinol filter with ... Offering a fully rapid exchange system, the ... the indicated applications:, Carotid Indication - ,The ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: